A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

CSU is a severe form of hives that affects around 1% of ... In CUPID STUDY B, IL-4 and IL-13 inhibitor Dupixent (dupilumab) wasn't able to achieve a significant improvement in symptoms in Xolair ...

Sanofi stock forms a Golden Cross, signaling bullish momentum as Dupixent nears FDA approval for bullous pemphigoid. SNY’s technicals remain strong, with all key moving averages trending higher ...